Edition:
United Kingdom

Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

31.80CAD
19 Oct 2018
Change (% chg)

$-0.33 (-1.03%)
Prev Close
$32.13
Open
$32.35
Day's High
$33.06
Day's Low
$31.76
Volume
1,137,327
Avg. Vol
895,095
52-wk High
$36.52
52-wk Low
$14.01

Latest Key Developments (Source: Significant Developments)

Bausch Health's Bryhali Lotion Receives Tentative FDA Approval
Monday, 8 Oct 2018 

Oct 8 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH'S BRYHALI™(HALOBETASOL PROPIONATE) LOTION, 0.01%, RECEIVES TENTATIVE FDA APPROVAL FOR PLAQUE PSORIASIS IN ADULTS.BAUSCH HEALTH COMPANIES INC - PLANS TO LAUNCH BRYHALI LOTION IN NOVEMBER 2018 UPON FINAL FDA APPROVAL.  Full Article

Dova, Salix Enter Exclusive Co-Promotion Agreement For Doptelet
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS & SALIX ENTER INTO EXCLUSIVE CO-PROMOTION AGREEMENT FOR DOPTELET® (AVATROMBOPAG).DOVA PHARMACEUTICALS - SALIX SALES FORCE WILL BEGIN SELLING DOPTELET IN MID-OCTOBER 2018.DOVA PHARMACEUTICALS - PURSUANT TO DEAL, CO WILL PAY SALIX A QTRLY FEE BASED ON NET SALES OF DOPTELET PRESCRIBED BY GASTROENTEROLOGISTS IN THE U.S..DOVA PHARMACEUTICALS - ENTERED INTO EXCLUSIVE AGREEMENT WITH SALIX PHARMACEUTICALS TO CO-PROMOTE DOVA'S DOPTELET IN UNITED STATES.  Full Article

Bausch Health Announces Xifaxan Intellectual Property Litigation Resolution
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ANNOUNCES RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION.BAUSCH HEALTH - SALIX PARTIES TO GRANT ACTAVIS NON-EXCLUSIVE LICENSE EFFECTIVE JAN. 1, 2028 TO SALIX PARTIES' IP FOR XIFAXAN 550 MG TABLETS IN U.S..BAUSCH HEALTH COMPANIES INC - WILL NOT MAKE ANY FINANCIAL PAYMENTS OR OTHER TRANSFERS OF VALUE AS PART OF AGREEMENT.BAUSCH HEALTH COMPANIES INC - PARTIES HAVE AGREED TO DISMISS ALL LITIGATION RELATED TO XIFAXAN.  Full Article

FDA Accepts Resubmission Of New Drug Application For Duobrii1 Lotion
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Bausch Health Companies Inc ::FDA ACCEPTS RESUBMISSION OF NEW DRUG APPLICATION FOR DUOBRII™1 (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION.BAUSCH HEALTH COMPANIES INC - PDUFA ACTION DATE OF FEBRUARY 15, 2019.  Full Article

Ortho Dermatologics Receives FDA Approval For Altreno (Tretinoin 0.05%) Lotion For Acne
Friday, 24 Aug 2018 

Aug 24 (Reuters) - Bausch Health Companies Inc ::ORTHO DERMATOLOGICS RECEIVES FDA APPROVAL FOR ALTRENO™ (TRETINOIN 0.05%) LOTION FOR ACNE.ALTRENO IS EXPECTED TO BE AVAILABLE DURING Q4 OF 2018.  Full Article

Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel
Monday, 9 Jul 2018 

July 9 (Reuters) - Valeant Pharmaceuticals International Inc ::BAUSCH + LOMB ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR LOTEPREDNOL ETABONATE OPHTHALMIC GEL, 0.38%.BAUSCH + LOMB - FDA HAS ACCEPTED NDA FOR ITS SUB-MICRON LOTEPREDNOL ETABONATE OPHTHALMIC GEL, 0.38% WITH PDUFA ACTION DATE OF FEBRUARY 25, 2019.  Full Article

Valeant Announces Pricing Of Private Offering Of Notes
Thursday, 17 May 2018 

Valeant Pharmaceuticals International Inc ::VALEANT ANNOUNCES PRICING OF PRIVATE OFFERING OF NOTES.VALEANT - UNIT PRICED PREVIOUSLY ANNOUNCED OFFERING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 8.50% UNSECURED SENIOR NOTES DUE 2027.  Full Article

Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating To Patent Infringement
Friday, 11 May 2018 

May 11 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT.PROGENICS PHARMA- CO,OTHER PLAINTIFFS ALLEGE PRODUCTS FOR WHICH PAR IS SEEKING U.S. MARKETING APPROVAL INFRINGES CO'S,OTHER PLAINTIFFS' U.S. PATENTS.  Full Article

Valeant Will Become Bausch Health Companies Inc
Tuesday, 8 May 2018 

May 8 (Reuters) - Valeant Pharmaceuticals International Inc ::VALEANT WILL BECOME BAUSCH HEALTH COMPANIES INC..VALEANT - AS PART OF NAME CHANGE, WILL ROLL OUT A NEW CORPORATE BRAND IDENTITY IN JULY 2018.VALEANT - NEW CORPORATE BRAND IDENTITY WILL INCLUDE NEW IMAGERY AND WEB SITE, AND WILL TRADE UNDER A NEW SYMBOL, BHC.  Full Article

Salix Receives FDA Approval For Plenvu, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies
Monday, 7 May 2018 

May 7 (Reuters) - Valeant Pharmaceuticals International Inc ::SALIX RECEIVES FDA APPROVAL FOR PLENVU®, NEXT GENERATION 1-LITER BOWEL CLEANSING PREPARATION FOR COLONOSCOPIES.SALIX RECEIVES FDA APPROVAL FOR PLENVU®, NEXT GENERATION 1-LITER BOWEL CLEANSING PREPARATION FOR COLONOSCOPIES.  Full Article

UPDATE 2-Bausch Health's plaque psoriasis lotion gets tentative FDA approval

Oct 8 Bausch Health Cos Inc , formerly Valeant Pharmaceuticals, said on Monday it received tentative U.S. approval to market its plaque psoriasis lotion, Bryhali.